Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects
NCT ID: NCT06926387
Last Updated: 2025-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
43 participants
INTERVENTIONAL
2025-04-17
2025-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects
NCT06920719
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects
NCT07265167
Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers
NCT06359626
Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers
NCT06613139
Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers
NCT06775522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects in group 1 will be administered "comparator" and "YHP2407" by crossover design on period 1, 2. Subjects in group 2 will be administered "YHP2407" and "comparator" by crossover design on period 1, 2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A(RT)
20 subjects, Cross-over, Single dose YHR2502 on period
1, Single dose of YHP2407 on period 2
YHP2407
Test drug: YHP2407, Comparator: YHR2502
YHR2502
Test drug: YHP2407, Comparator: YHR2502
B(TR)
20 subjects, Cross-over, Single dose of YHP2407 on period 1, Single dose of YHR2502 on period 2
YHP2407
Test drug: YHP2407, Comparator: YHR2502
YHR2502
Test drug: YHP2407, Comparator: YHR2502
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YHP2407
Test drug: YHP2407, Comparator: YHR2502
YHR2502
Test drug: YHP2407, Comparator: YHR2502
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those without clinically significant congenital or chronic diseases
Exclusion Criteria
* Others who are judged ineligible to participate in the trial by the principal investigator.
* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.
19 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yuhan Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyejin Lim
Role: PRINCIPAL_INVESTIGATOR
Gimpo Woori Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gimpo Woori Hospital
Gimpo-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YHP2407-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.